BridgeMD
J2A-MC-GZPO: A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes J2A-MC-GZP1: A Study of Orforglipron (LY3502970) in Participants with Obesity or Overweight and at Least One Weight-Related Comorbidity J2A-MC-GZP2: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
EU CTIS ID: 2025-521098-14-00
What this study is testing
GZPO: The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1 (do not have type 2 diabetes) or J2A-MC-GZP2 (have type 2 diabetes). GZP1: The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overweight and at least one other related health condition (excluding type 2 diabetes). This trial is part of the master protocol study J2A-MC-GZPO. GZP2: The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- (GZP1) Have body mass index (BMI) ≥30 kilograms per square meter (kg/m2) or BMI ≥25.0 kg/m2 and at least 1 of the following weight-related comorbidities at screening: • hypertension • dyslipidemia • obstructive sleep apnea, or • cardiovascular disease
- (GZP1) Have a history of at least one unsuccessful dietary effort to lose body weight
- (GZP2) Have body mass index (BMI) ≥25 kilograms per square meter (kg/m2) at screening
- (GZP2) Have type 2 diabetes
- (GZP2) Have hemoglobin A1c (HbA1c) ≥7% and ≤10% at screening
- (GZP2) Have a history of at least one unsuccessful dietary effort to lose body weight
You likely can't join if
- (GZP1) Have type 1 diabetes, type 2 diabetes, or any other types of diabetes
- (GZP2) Have type 1 diabetes
- (GZP1, GZP2) Have an unstable body weight within 90 days prior to screening
- (GZP1, GZP2) Have New York Heart Association functional classification IV congestive heart failure or an acute cardiovascular condition within 90 days prior to screening
- (GZP1, GZP2) Have acute or chronic hepatitis or pancreatitis
- (GZP1, GZP2) Are taking other medications or alternative remedies to manage weight loss
The study team makes the final eligibility decision.
Where it's taking place
- Mexico
- Japan
- United States
- India
- Argentina
- China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Mexico; Japan; United States; India; Argentina; China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.